AliveCor, which specialises in FDA-cleared personal electrocardiogram (EKG) technology, announced the issuance of a US patent which covers the use of data collected from wearable devices as a means of assisting the diagnosis of heart arrhythmias, including those that may be asymptomatic.
AliveCor said the patent entitled “Discordance Monitoring” describes the analysis of heart rate data and activity data from wearable devices in order to trigger notifications for users to take an EKG when there is a difference between these two biometrics.
It said disagreement between a user’s heart rate and activity level could be suggestive of any number of heart problems, including asymptomatic Atrial Fibrillation.
“Medical capture of asymptomatic heart arrhythmias is an ongoing challenge,” said AliveCor Founder and Chief Medical Officer, Dr. David Albert.
“Holter monitors, implantable recorders, and patches, all present various levels of inconvenience and discomfort.
“Our technology suggests a future in which detection of heart arrhythmias can be non-invasive, ultra-convenient, and highly reliable.”
AliveCor is in clinical trials to assess whether its SmartRhythm feature can be effective in the detection of a broad range of asymptomatic arrhythmias.
SmartRhythm, a component of AliveCor’s app for Apple Watch and iPhone, uses artificial intelligence in concert with inputs from Apple Watch’s heart rate and activity sensors to continuously evaluate the correlation between heart activity and physical activity.
When SmartRhythm detects that heart rate and activity are out of sync, the device notifies users to capture an EKG with KardiaBand, or with KardiaMobile, AliveCor’s portable EKG reader.